The eligibility of AUVI-Q’s Electronic Prompt System for preferential tariff treatment under the Nairobi Protocol from Thailand
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated December 2, 2025, you requested a tariff classification ruling on behalf of your client, Kaleo, Inc. The samples were received, examined, and disposed of. The Electronic Prompt System is designed for incorporation in the AUVI-Q (epinephrine injection, USP), a compact auto-injector that provides gas-powered injection of epinephrine and automatic needle retraction.
The Electronic Prompt System consists of a miniature speaker, battery contact arm, flexible circuit board, voice microchip, stacked batteries, red and green light emitting diodes (“LEDs”), tear-through switches, and an electronics cover designed to fit with the housing of the AUVI-Q. It provides audible cues for use in the form of voice instructions and beeps, as well as providing visual cues in the form of red and green blinking LEDs.
The purpose of the Electronic Prompt System is to assist in guiding the AUVI-Q user, whether the patient or a third-party, through the use of the AUVI-Q in administering a life-saving dose of epinephrine during a severe allergic reaction.
The system assists the user in locating certain components and the audible instructions prompt the user to take specific actions (like removing the red safety guard ) or to wait to take an action (including how long to hold the device in place during the injection process).You state that the Electronic Prompt System is specially designed for incorporation in the AUVI-Q; it cannot be used with or incorporated into any other article.
The Electronic Prompt System is imported and incorporated with the unfinished AUVI-Q in the United States to create the assembled combination product. You also state that the AUVI-Q is a prescription-only epinephrine delivery device for immediate emergency treatment of individuals experiencing type I allergic reactions, including anaphylaxis, triggered by allergens such as pollen, foods, or insect stings.
In your submission you requested consideration of a secondary classification under 9817.00.96, Harmonized Tariff Schedule of the United Sates (HTSUS), which applies to articles and parts and accessories of articles specifically designed or adapted for the use or benefit of the permanently or chronically physically or mentally handicapped.
Subheading 9817.00.96, HTSUS, covers: “Articles specially designed or adapted for the use or benefit of the blind or other physically or mentally handicapped persons; parts and accessories (except parts and accessories of braces and artificial limb prosthetics) that are specially designed or adapted for use in the foregoing articles . . .
Other.” The term “blind or other physically or mentally handicapped persons” includes “any person suffering from a permanent or chronic physical or mental impairment which substantially limits one or more major life activities, such as caring for one’s self, performing manual tasks, walking, seeing, hearing, speaking, breathing, learning, or working.” U.S. Note 4(a), Subchapter XVII, Chapter 98, HTSUS.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N356618).